4.8 Article

Cell-cycle-regulated control of VSG expression site silencing by histones and histone chaperones ASF1A and CAF-1b in Trypanosoma brucei

Journal

NUCLEIC ACIDS RESEARCH
Volume 40, Issue 20, Pages 10150-10160

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gks813

Keywords

-

Funding

  1. Wellcome Trust [089172]

Ask authors/readers for more resources

Antigenic variation in African trypanosomes involves monoallelic expression and reversible silencing of variant surface glycoprotein (VSG) genes found adjacent to telomeres in polycistronic expression sites (ESs). We assessed the impact on ES silencing of five candidate essential chromatin-associated factors that emerged from a genome-wide RNA interference viability screen. Using this approach, we demonstrate roles in VSG ES silencing for two histone chaperones. Defects in S-phase progression in cells depleted for histone H3, or either chaperone, highlight in particular the link between chromatin assembly and DNA replication control. S-phase checkpoint arrest was incomplete, however, allowing G(2)/M-specific VSG ES derepression following knockdown of histone H3. In striking contrast, knockdown of anti-silencing factor 1A (ASF1A) allowed for derepression at all cell cycle stages, whereas knockdown of chromatin assembly factor 1b (CAF-1b) revealed derepression predominantly in S-phase and G(2)/M. Our results support a central role for chromatin in maintaining VSG ES silencing. ASF1A and CAF-1b appear to play constitutive and DNA replication-dependent roles, respectively, in the recycling and assembly of chromatin. Defects in these functions typically lead to arrest in S-phase but defective cells can also progress through the cell cycle leading to nucleosome depletion and derepression of telomeric VSG ESs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

A post-transcriptional respiratome regulon in trypanosomes

Anna Trenaman, Lucy Glover, Sebastian Hutchinson, David Horn

NUCLEIC ACIDS RESEARCH (2019)

Article Biochemistry & Molecular Biology

Suramin exposure alters cellular metabolism and mitochondrial energy production in African trypanosomes

Martin Zoltner, Gustavo D. Campagnaro, Gergana Taleva, Alana Burrell, Michela Cerone, Ka-Fai Leung, Fiona Achcar, David Horn, Sue Vaughan, Catarina Gadelha, Alena Zikova, Michael P. Barrett, Harry P. de Koning, Mark C. Field

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Article Microbiology

Spatial integration of transcription and splicing in a dedicated compartment sustains monogenic antigen expression in African trypanosomes

Joana Faria, Vanessa Luzak, Laura S. M. Muller, Benedikt G. Brink, Sebastian Hutchinson, Lucy Glover, David Horn, T. Nicolai Siegel

Summary: The study reveals a mechanism in Trypanosoma brucei where a single expressed antigen-coding gene interacts with a major messenger RNA splicing locus in a specific nuclear compartment, ensuring monogenic expression. Specific proteins VEX1 and VEX2 are associated with an antigen exclusion complex, playing a role in this process of antigen transcription and mRNA splicing. Depletion of VEX2 results in loss of monogenic antigen expression and increased interactions between previously silent antigen genes and the splicing locus.

NATURE MICROBIOLOGY (2021)

Article Biochemistry & Molecular Biology

TbSAP is a novel chromatin protein repressing metacyclic variant surface glycoprotein expression sites in bloodstream form Trypanosoma brucei

Carys Davies, Cher-Pheng Ooi, Georgios Sioutas, Belinda S. Hall, Haneesh Sidhu, Falk Butter, Sam Alsford, Bill Wickstead, Gloria Rudenko

Summary: The African trypanosome Trypanosoma brucei relies on a protective VSG coat for survival in mammalian hosts. A whole genome RNAi library screen identified a novel DNA binding protein TbSAP, which plays an important role in silencing the extensive VSG repertoire in bloodstream form T. brucei.

NUCLEIC ACIDS RESEARCH (2021)

Review Parasitology

Genome-scale RNAi screens in African trypanosomes

David Horn

Summary: Genome-scale genetic screens have played a crucial role in African trypanosomes by uncovering mechanisms related to drug resistance, metabolism, and gene expression control. They have also been effective in identifying potential antitrypanosomal drug targets.

TRENDS IN PARASITOLOGY (2022)

Article Multidisciplinary Sciences

Synthetic biology tools for engineering Goodwin oscillation in Trypanosoma brucei brucei

Yanika Borg, Sam Alsford, Vasos Pavlika, Alexei Zaikin, Darren N. Nesbeth

Summary: Kinetoplastid protozoa, with unique properties, have been shown to hold bioengineering potential. This study successfully constructed an oscillatory gene network in Trypanosoma brucei for the first time, laying the foundation for future synthetic biology research.

HELIYON (2022)

Article Biochemistry & Molecular Biology

Oligo targeting for profiling drug resistance mutations in the parasitic trypanosomatids

Simone Altmann, Eva Rico, Sandra Carvalho, Melanie Ridgway, Anna Trenaman, Hannah Donnelly, Michele Tinti, Susan Wyllie, David Horn

Summary: This study reports a simple method for rapid and precise editing of priority drug targets in trypanosomatids. By targeting and editing drug targets, combined with sequencing technology, potential impacts on drug efficacy can be assessed quickly.

NUCLEIC ACIDS RESEARCH (2022)

Article Microbiology

Control of Variant Surface Glycoprotein Expression by CFB2 in Trypanosoma brucei and Quantitative Proteomic Connections to Translation and Cytokinesis

Gustavo Bravo Ruiz, Michele Tinti, Melanie Ridgway, David Horn

Summary: VSG expression plays a crucial role in parasite virulence and is a fascinating subject in extreme biology. This study identified three candidate VSG regulators and demonstrated the role of CFB2 in controlling VSG expression through the VSG 3' UTR. Additionally, insights into the connections between VSG expression control, ribosomal protein expression, and cytokinesis were revealed.

MSPHERE (2022)

Correction Microbiology

Anti-trypanosomatid drug discovery: progress and challenges (vol 5, pg 217, 2017

Manu De Rycker, Susan Wyllie, David Horn, Kevin D. Read, Ian H. Gilbert

NATURE REVIEWS MICROBIOLOGY (2022)

Review Microbiology

Anti-trypanosomatid drug discovery: progress and challenges

Manu De Rycker, Susan Wyllie, David Horn, Kevin D. Read, Ian H. Gilbert

Summary: Leishmaniasis, Chagas disease, and human African trypanosomiasis are major causes of death and illness, particularly in low- and middle-income countries. The development of new medicines for leishmaniasis and Chagas disease is urgently needed, with limited progress in the clinical pipeline for Chagas disease. This review provides an overview of recent advances in understanding the biology of these pathogens, with a focus on drug discovery, as well as the development of new drug candidates and potential solutions to overcome challenges in clinical development.

NATURE REVIEWS MICROBIOLOGY (2023)

Article Multidisciplinary Sciences

Genome-scale RNA interference profiling of Trypanosoma brucei cell cycle progression defects

Catarina A. Marques, Melanie Ridgway, Michele Tinti, Andrew Cassidy, David Horn

Summary: In this study, a genome-wide RNA-interference library screen was used to investigate the cell cycle defects in Trypanosoma brucei. The results provide comprehensive functional genomic evidence for the known and novel machineries, pathways, and regulators that coordinate trypanosome cell cycle progression.

NATURE COMMUNICATIONS (2022)

Article Chemistry, Medicinal

Bis-6-amidino-benzothiazole Derivative that Cures Experimental Stage 1 African Trypanosomiasis with a Single Dose

Livio Racane, Lucija Pticek, Sanja Kostrun, Silvana Raic-Malic, Martin Craig Taylor, Michael Delves, Sam Alsford, Francisco Olmo, Amanda Fortes Francisco, John M. Kelly

Summary: We designed and synthesized a series of symmetric benzothiazole derivatives and evaluated their efficacy against Trypanosoma brucei and Plasmodium falciparum. One compound showed high selectivity and trypanocidal activity, curing mice infected with trypanosomiasis. It also exhibited activity against the malaria parasite.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Microbiology

Competition among variants is predictable and contributes to the antigenic variation dynamics of African trypanosomes

Douglas Escrivani, Viktor Scheidt, Michele Tinti, Joana Faria, David Horn

Summary: Some pathogens use antigenic variation to evade mammalian host adaptive immune responses. African trypanosomes employ variant surface glycoproteins (VSGs) to continually switch their active VSGs and avoid immune recognition. Switched trypanosomes compete in a predictable manner that is dependent on the activated VSG, and the population of cells that activates minichromosome derived VSGs has a competitive advantage.

PLOS PATHOGENS (2023)

Article Microbiology

Genome-wide screens connect HD82 loss-of-function to purine analog resistance in African trypanosomes

Anna Trenaman, Michele Tinti, Abdelmadjid Atrih, David Horn

Summary: Nucleoside analogs are widely used as anti-infective agents, but their potential as anti-parasitic agents has not been fully explored. This study identified two proteins, Tb927.6.2800 and HD82, associated with purine analog resistance in African trypanosomes. The findings also validated two nucleoside kinases involved in pro-drug activation. HD82, related to the mammalian nuclear viral restriction factor SAMHD1, sensitized trypanosomes to nucleoside analogs by reducing native nucleotide pools. This study provides insights into nucleoside/nucleotide metabolism and nucleoside analog resistance in trypanosomatids.

MSPHERE (2023)

Review Microbiology

Anti-trypanosomatid drug discovery: progress and challenges

Manu De Rycker, Susan Wyllie, David Horn, Kevin D. Read, Ian H. Gilbert

Summary: Leishmaniasis, Chagas disease, and human African trypanosomiasis are causing significant death and morbidity, especially in low- and middle-income countries. There is a critical need for new medications for leishmaniasis and Chagas disease, while the clinical development pipeline for Chagas disease remains sparse. This review discusses recent advancements in understanding the biology of these pathogens, with a focus on drug discovery, and explores progress in developing new drug candidates and identifying potential molecular targets. The challenges in developing new clinical candidates are also discussed, along with potential solutions to overcome these hurdles.

NATURE REVIEWS MICROBIOLOGY (2023)

No Data Available